In 1999, Acacia Biosciences was acquired by Rosetta Inpharmatics, itself a wholly owned subsiduary of Merck Pharmaceuticals. Acacia Biosciences is a drug discovery technology company committed to the creation of proprietary assay systems and databases that facilitate the rapid development of biopharmaceutical sand agricultural chemicals. The Genome Reporter Matrix is the first in a series of novel tools that provide practical analysis of early stage chemicals by interpreting their effects across entire genomes. In addition to the GRM, Acacia's technology is used to discover novel targets and gene regulatory mechanisms.
